- Direction
- Unknown
- Own history
- —
- Peers
- —
- Persistence
- TRANSIENT
· Pharmaceutical Preparations
RESEARCH SNAPSHOTNRX Pharmaceuticals, Inc.'s latest supported as-filed period reports revenue of $1.1M. Every value below links to its SEC accession and metric lineage.
No material rule-based research observation currently meets GrossPattern's Insight value threshold. Current state, direction, and filing evidence remain available below.
Separate current dimensions—not a universal score or investment ranking.
A multidimensional view of the latest comparable filing—not a composite score or recommendation.
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value -806.09% · OPTIONAL
Level · gp.fundamentals.gross_margin
Raw value 38.69% · CORE
Level · gp.fundamentals.operating_margin
Raw value -590.83% · CORE
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
Raw value 192.19% · OPTIONAL
Level · gp.fundamentals.sbc_revenue_ratio
Raw value 12.62% · OPTIONAL
Business direction, financial quality, capital allocation, and governance evidence remain separate—never collapsed into a recommendation score.
Interpretation boundary Direction describes measurable company fundamentals. Governance reports observable evidence only; it does not grade management character or predict stock returns.
Latest available comparable states within 180 days, normalized with robust median/MAD statistics.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Operating cash flow changed -120.3% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Cash & equivalents changed +817.0% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
NRXP · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001437749-26-032828SEC ↗8-KOct 5, 2026Period Sep 29, 20260001437749-26-032042SEC ↗8-KSep 16, 2026Period Sep 15, 20260001437749-26-030492SEC ↗8-KSep 14, 2026Period Sep 8, 20260001437749-26-030228SEC ↗8-KAug 17, 2026Period Aug 17, 20260001437749-26-028111SEC ↗10-QAug 14, 2026Period Jun 30, 20260001437749-26-028027SEC ↗8-KAug 7, 2026Period Aug 7, 20260001437749-26-026428SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Jan 27, 2026Filed Feb 17, 2026 | Casper Joseph MichaelChief Operating Officer | Grant Or AwardDirect | 100,000 | $0 | $0 | Form 4 ↗ |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Current assets changed +535.3% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Total assets changed +606.1% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Working capital changed +86.8% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Shares outstanding changed +119.7% from the comparable as-filed period. The change ranks at the 86th percentile of 7 prior comparable changes.
Operating income changed -74.4% from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001437749-26-024037